Common hormone therapies include: HER2-Positive Breast Cancer: Drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) target the HER2 protein, which promotes cancer cell growth. CDK4/6 Inhibitors ...

Dr. Dennis Slamon, director of clinical/translational research and the Revlon/UCLA Women’s Cancer Research Program at Jonsson ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of ...

My daughter faced the difficult decision of balancing the potential benefits and risks of cancer treatment, including the long-term heart complications associated with Herceptin.

Canopy, the first Continuous Care Platform for oncology, today announced the strategic expansion of its leadership team with the appointments of Josh Neiman as President and Chief Commercial Officer ...

Our updated guideline on menopause, published today, emphasises the importance of an individualised approach and shared decision-making when making choices about treatment for symptoms. Around 5.3 ...

For example, the multinational Roche extended the exclusivity of trastuzumab (Herceptin), a biologic used to treat breast cancer, by introducing a subcutaneous version just as the original patent was ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

This week’s recap highlights several significant FDA developments. We also cover ongoing successes of pembrolizumab with chemotherapy in NSCLC.